logo-loader
RNS
viewFutura Medical PLC

Futura Medical PLC - Remuneration of NED and Total Voting Rights

RNS Number : 6268A
Futura Medical PLC
22 January 2020
 

Remuneration of Non-Executive Directors and Total Voting Rights

 

22 January 2020

 

Futura Medical plc (AIM: FUM) (the "Company"), a pharmaceutical company developing a portfolio of innovative products for sexual health and pain relief, announces the issue of 341,659 new ordinary shares of 0.2 pence each ("Ordinary Shares") in respect of the 2019 remuneration of its Non-Executive Directors.

 

In accordance with the terms of their service agreements, the Non-Executive Directors receive approximately 30 per cent of their remuneration in the form of Ordinary Shares. For 2019, these were issued at 6.01 pence per share, being the average closing mid-market price of the last 10 trading days of 2018 (as announced via RNS on 11 January 2019).

 

The 341,659 new Ordinary Shares shall rank pari passu with the existing issued Ordinary Shares of the Company and have been issued as follows:

 

Director

Number of Ordinary Shares issued for 2019 remuneration

Total number of ordinary shares held

Percentage of the Company's resulting issued share capital

John Clarke

256,562

512,788

0.21%

Jonathan Freeman

85,097

175,718

0.07%

 

Application has been made to the London Stock Exchange and it is anticipated that trading of the new Ordinary Shares will commence on AIM at 8:00am on 28 January 2020.

 

Immediately following the above issue, the Company will have 245,626,926 ordinary shares in issue, each carrying one voting right. Since the Company currently holds no shares in treasury, the total number of voting rights in the Company is therefore 245,626,926 and this figure may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

The shares element of the Non-Executive Directors' remuneration for 2020 will be awarded at 12.24 pence per Ordinary Share, being the average closing mid-market price of the last 10 trading days of 2019. The Non-Executive Directors will receive these shares in January 2021.

 

Further details are contained within the notifications below, made in accordance with Article 19 of the EU Market Abuse Regulation 596/2014. Full details of the Non-Executive Directors' remuneration will be included in the Company's Annual Report & Accounts.

ENDS

 

For further information please contact:

Futura Medical plc 
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO

Email: [email protected]
Tel: +44 (0) 1483 685 670
www.Futuramedical.com

 

Nominated Adviser and Sole Broker:
Liberum
Bidhi Bhoma/ Euan Brown/ Kane Collings
Tel: +44 (0) 20 3100 2000

 

For media enquiries please contact:

Optimum Strategic Communications

Mary Clark/ Eva Haas/ Hollie Vile

Email: [email protected]

Tel: +44 (0) 203 950 9144

Notes to editors

 

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology. These products are optimised for clinical efficacy, safety, administration and patient convenience and are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.

 

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

 

Name

John Clarke

2

Reason for the notification

a)

 

Position/status

 

Director/ PDMR

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

 

Futura Medical plc

b)

 

LEI

 

21380053QLT46UNV2303

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

 

Ordinary shares of 0.2p each

 

GB0033278473

b)

 

Nature of the transaction

 

Issue of shares

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

6.01 pence

256,562

 

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

 

 

 

Not applicable

 

 

e)

 

Date of the transaction

 

22 January 2020

f)

 

Place of the transaction

 

Outside of trading venue

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

 

Name

 

Jonathan Freeman

2

Reason for the notification

a)

 

Position/status

 

Director/ PDMR

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

 

Futura Medical plc

b)

 

LEI

 

21380053QLT46UNV2303

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

Ordinary shares of 0.2p each

 

GB0033278473

b)

 

Nature of the transaction

 

Issue of shares

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

6.01 pence

85,097

 

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

 

 

 

Not applicable

 

 

e)

 

Date of the transaction

 

22 January 2020

f)

 

Place of the transaction

 

Outside of trading venue

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
TVRUUOSRRAUAUAR

Quick facts: Futura Medical PLC

Price: 18.0001

Market: AIM
Market Cap: £44.21 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Futura Medical kicks off work on Phase III trial for erectile dysfunction gel

James Barder, chief executive of Futura Medical PLC (LON:FUM), tells Proactive they've begun preparatory work on the first Phase III efficacy trial for MED2002 - their topical gel for erectile dysfunction (ED). The study will recruit approximately 1,000 patients with mild, moderate and...

on 27/4/18